Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- Patients who has been receiving dietary therapy and a stable dose and regimen of insulin over 8 weeks before at the time of an observation term start
- Patients whose HbA1c at the time of an observation term start is 7.5% or more and less than 10.0%
- Patients who has been receiving dietary therapy and a stable dose and regimen of insulin over 8 weeks before at the time of an observation term start
- Patients whose HbA1c at the time of an observation term start is 7.5% or more and less than 10.0%
Exclusion Criteria
- Type 1 Diabetes Mellitus
- Patients with serious diabetic complications and other serious complications
- Type 1 Diabetes Mellitus
- Patients with serious diabetic complications and other serious complications
Summary
- Conditions
- Type 2 Diabetes Mellitus
- Type
- Interventional
- Phase
- Phase 4
Participation Requirements
- Age
- Between 20 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- Patients who has been receiving dietary therapy and a stable dose and regimen of insulin over 8 weeks before at the time of an observation term start
- Patients whose HbA1c at the time of an observation term start is 7.5% or more and less than 10.0%
- Patients who has been receiving dietary therapy and a stable dose and regimen of insulin over 8 weeks before at the time of an observation term start
- Patients whose HbA1c at the time of an observation term start is 7.5% or more and less than 10.0%
Exclusion Criteria
- Type 1 Diabetes Mellitus
- Patients with serious diabetic complications and other serious complications
- Type 1 Diabetes Mellitus
- Patients with serious diabetic complications and other serious complications
Tracking Information
- NCT #
- NCT02154347
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon